When it comes to matching the commercial scale-up to the innovations taking place across Kite’s pipeline, Alquist admitted ...

The FDA signed off on Breztri’s new use after reviewing data from a pair of phase 3 studies, KALOS and LOGOS, which assessed ...

Earlier this year, when the FDA asked Amgen to pull its rare disease drug Tavneos from the market, the California drugmaker ...

Novartis CEO Vas Narasimhan says Europe needs a “complete rethink” of how it prices its drugs, warning that the entrance of ...

Novartis CEO Vas Narasimhan is doubling down on his $5 billion peak sales projection for Pluvicto, even as the company has ...

GSK’s Tesaro unit took a blow in its legal feud with Jemperli developer AnaptysBio, with a Delaware court dismissing GSK’s ...

Rocket Pharmaceuticals has offloaded its lucrative FDA rare pediatric disease priority review voucher (PRV), striking a $180 ...

Pfizer inking the last of three settlements to postpone copycats to its transthyretin amyloid cardiomyopathy (ATTR-CM) med ...

Haleon has kicked off a soccer-focused marketing campaign ahead of the Fifa World Cup coming to the U.S., putting midfielder ...

Already the largest biopharma company in India, generics powerhouse Sun Pharma has doubled in size with its acquisition (PDF) ...

With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift ...

As Pfizer gears up to defend its patents on transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis in court this week, ...